LBA60 Phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)

作者：Zhenwei Peng, Jingjing Wang, Yuting Zhang, Huiyu Li, Qun Zhao, Xiaodong Zhu, S. Wei, Yangyang Cheng, Wenyu Yang, Jie Yao, Mingyang Zhang, Li Xie, Xian Zhang, Peng Zhao, Chengguang Hu, Jing Zhang, Zhenchang Wang, Wenxue Wang, Huan Han, Lin Shen · 发表于：Annals of Oncology · 年份：2024 · DOI：10.1016/j.annonc.2024.08.2302 · 被引用次数：14 · 研究领域：Gastric Cancer Management and Outcomes、Colorectal Cancer Treatments and Studies、Gastrointestinal Tumor Research and Treatment